CTLA4 and neoplasm: Furthermore, in vivo studies showed that the NP vaccine could elicit a strong, antigen-specific CTL response against 4T1 TNBC cells and that combined treatment with a CTLA-4-siRNA-containing NLE could significantly enhance the anti-tumor immune response compared to the vaccine or CTLA-4-siRNA alone.